• Physician reported outcome of the first chemotherapy utilized following the receipt of a final report from ChemoFx® in solid tumor malignancies for the generation of hypotheses for further sub-study. [ Time Frame: 24-36 Months depending on Disease Status ] [ Designated as safety issue: No ]
  

• Identify possible enhancements of the predictive and prognostic capabilities of the assay through the inclusion of molecular markers and biological growth factors [ Time Frame: 24-36 Months depending on Disease Status ] [ Designated as safety issue: No ]
  

The traditional treatment course for new cases of many gynecologic cancers is cytoreductive surgery followed by chemotherapy. Unfortunately, despite high initial response rates to treatment, the majority of patients recur. The use of ineffective chemotherapy can result in unnecessary toxicity and costs, delay of more effective treatment, and the potential for the development of cross-resistance to additional drugs. The ability to individualize therapy by providing the treating physician with ex vivo response information on a panel of drugs should aid in the selection of effective therapy for individual patients, thus resulting in improved outcomes.

Resistance to chemotherapy cannot be predicted by either clinical or histological examination. Historically, the ex vivo sensitivity and resistance of tumor cells has been evaluated as a tool for predicting the clinical response of the patient to therapy. In this study, patients will be followed through treatment; the assay results will be compared to clinical outcomes that will be reported at regular intervals. Tumor pathology slides and excess tumor cells (if available) will be used to characterize common polymorphisms in drug metabolizing enzymes as well as other molecular markers potentially associated with tumor response.

The Observational Study seeks to enroll an estimated 3,000 patients from 150 academic and community-based physicians in the U.S. The patients will be treated with drugs and/or drug combinations based on the medical judgment of the treating physician. This study is not randomized.